DCLK1 and non-small cell lung carcinoma: Ge et al. [109] identified a significant upregulation of SNHG1 in cisplatin-resistant NSCLC tissues and cells, subsequently proposing and validating its role in upregulating doublecortin-like kinase 1 (DCLK1) expression through targeting miR-330-5p, thereby augmenting the resistance of NSCLC cells to cisplatin.